Immunome Inc. — Investor Relations & Filings
Immunome Inc. is a clinical-stage oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company specializes in creating first-in-class and best-in-class therapeutic candidates, with a primary focus on Antibody-Drug Conjugates (ADCs) and Radioligand Therapies (RLTs). Immunome utilizes a systematic, data-driven process to optimize each component of its drug candidates—antibody, linker, and payload—to address high unmet medical needs. Its clinical pipeline includes varegacestat, a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; IM-1021, a ROR1-targeted ADC in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand. The company also advances a portfolio of preclinical ADCs targeting various solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Immunome Inc. (0001472012) (Filer) | 2026-04-24 | English | |
| SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject) | 2026-03-26 | English | |
| 4 - Immunome Inc. (0001472012) (Issuer) | 2026-03-24 | English | |
| 144 - Immunome Inc. (0001472012) (Subject) | 2026-03-20 | English | |
| 10-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English | |
| 8-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 36260617 | ARS - Immunome Inc. (0001472012) (Filer) | 2026-04-24 | English | ||
| 33050365 | SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject) | 2026-03-26 | English | ||
| 33017259 | 4 - Immunome Inc. (0001472012) (Issuer) | 2026-03-24 | English | ||
| 33000829 | 144 - Immunome Inc. (0001472012) (Subject) | 2026-03-20 | English | ||
| 32892309 | 10-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English | ||
| 32892308 | 8-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English | ||
| 29982218 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
|
2025
8 filings
| |||||
| 12302604 | Director's Dealing 2025 | 2025-12-31 | English | ||
| 12302605 | Director's Dealing 2025 | 2025-12-23 | English | ||
| 12302609 | Major Shareholding Notification 2025 | 2025-12-23 | English | ||
| 12302606 | Director's Dealing 2025 | 2025-12-22 | English | ||
| 12302607 | Director's Dealing 2025 | 2025-12-22 | English | ||
| 12302608 | Director's Dealing 2025 | 2025-12-22 | English | ||
| 12302610 | Director's Dealing 2025 | 2025-12-18 | English | ||
| 12302611 | 8-K | 2025-12-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Coeptis Therapeutics Holdings, Inc.
Biopharmaceutical company developing cell therapy platforms…
|
COEP | US | Manufacturing |
|
Cogent Biosciences, Inc.
A clinical-stage biotech company developing precision thera…
|
COGT | US | Manufacturing |
|
Cohance Lifesciences Limited
Global CDMO and API platform offering end-to-end solutions …
|
COHANCE | IN | Manufacturing |
|
Coherus Oncology, Inc.
Biopharmaceutical company developing and commercializing im…
|
CHRS | US | Manufacturing |
|
Colinz Laboratories ltd.
Manufactures and markets medicinal formulations across dive…
|
531210 | IN | Manufacturing |
|
COLLEGIUM PHARMACEUTICAL, INC
A biopharmaceutical company developing abuse-deterrent pain…
|
COLL | US | Manufacturing |
|
CollPlant Biotechnologies Ltd
Develops plant-derived collagen for 3D bioprinting of tissu…
|
CLGN | US | Manufacturing |
|
COMPASS Pathways plc
Develops psilocybin treatments for difficult-to-treat menta…
|
CMPS | GB | Manufacturing |
|
Compass Therapeutics, Inc.
Clinical-stage biopharma developing antibody-based therapeu…
|
CMPX | US | Manufacturing |
|
Concord Biotech Limited
R&D-driven producer of fermentation-based APIs and formulat…
|
CONCORDBIO | IN | Manufacturing |
Immunome Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32238/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32238 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32238 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32238 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32238}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Immunome Inc. (id: 32238)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.